Form 4: T2 Biosystems CEO Awarded 980,000 Restricted Stock Units

T2 Biosystems CEO, John J. Sperzel III, was granted 980,000 restricted stock units (RSUs) in two tranches, contingent on shareholder approval of an amended incentive plan.

Summary

• T2 Biosystems CEO, John J. Sperzel III, received a grant of 980,000 restricted stock units (RSUs) on November 4, 2024.
• The RSUs are divided into two equal tranches of 490,000 units each.
• The first tranche of 490,000 RSUs vests in one installment on May 4, 2025.
• The second tranche of 490,000 RSUs vests in three equal annual installments beginning on November 4, 2025.
• Both grants were contingent on shareholder approval of the amendment and restatement of the company's 2014 Incentive Award Plan.
• Shareholders approved the plan amendment on December 30, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term performance and retention of the CEO.
• Shareholder approval of the incentive plan amendment demonstrates support for the company's compensation strategy.

Risks

• The vesting of a large number of shares could potentially dilute existing shareholders if not managed carefully.
• The value of the RSUs is dependent on the future performance of the company's stock price.

Future Outlook

The document does not contain any specific forward-looking statements or guidance, it only details the grant of RSUs to the CEO.

Management Comments

• The document includes the signature of John Sprague, Attorney-in-fact, on behalf of John J. Sperzel III.

Industry Context

The granting of stock-based compensation to executives is a common practice in the biotechnology industry to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock-based compensation is a standard practice for executive compensation in the biotech industry.
• The vesting schedule of the RSUs is typical, with a mix of single and multi-year vesting periods.
• Companies like Exact Sciences (EXAS) and Bio-Rad Laboratories (BIO) also use stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it incentivizes the CEO to improve company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

Restricted Stock Units, RSU, Incentive Award Plan, Executive Compensation, Shareholder Approval, Vesting, T2 Biosystems, TTOO